# A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

> **NCT01201915** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 74 (actual)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT01201915
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01201915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01201915, "A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01201915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*